Hims & Hers Health (NYSE:HIMS) Shares Down 1.1% Following Insider Selling

Key Points

• Hims & Hers Health's stock price fell by 1.1% to $44.87 amid insider selling activity, with a significant drop in trading volume compared to the average.
• Insiders, including CEO Andrew Dudum, sold a total of over 130,000 shares recently, resulting in a substantial decrease in their ownership stakes.
• Analysts have set varying price targets for the stock, with a consensus target price of $38.92, and the company reported mixed quarterly earnings results, missing EPS expectations.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s stock price fell 1.1% during mid-day trading on Wednesday following insider selling activity. The stock traded as low as $44.64 and last traded at $44.87. 7,539,135 shares traded hands during trading, a decline of 77% from the average session volume of 33,440,219 shares. The stock had previously closed at $45.35.

Specifically, insider Soleil Boughton sold 2,571 shares of the firm's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $44.53, for a total transaction of $114,486.63. Following the completion of the transaction, the insider owned 150,450 shares in the company, valued at approximately $6,699,538.50. This trade represents a 1.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $45.06, for a total transaction of $5,773,402.62. Following the transaction, the chief executive officer owned 89,521 shares of the company's stock, valued at approximately $4,033,816.26. This trade represents a 58.87% decrease in their position. The disclosure for this sale can be found here.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a research report on Monday, June 23rd. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Piper Sandler restated a "neutral" rating and set a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Zacks Research cut shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Two research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat, Hims & Hers Health has an average rating of "Reduce" and a consensus target price of $38.92.

Hims & Hers Health Stock Performance

The company has a market cap of $10.10 billion, a P/E ratio of 56.17, a price-to-earnings-growth ratio of 2.90 and a beta of 2.08. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The stock's 50-day moving average price is $51.10 and its 200 day moving average price is $45.85.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. During the same period in the prior year, the business earned $0.06 EPS. The company's revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors have recently modified their holdings of the company. Virtus Advisers LLC acquired a new stake in shares of Hims & Hers Health in the second quarter worth $26,000. Quaker Wealth Management LLC acquired a new stake in shares of Hims & Hers Health in the second quarter worth $29,000. Bessemer Group Inc. grew its stake in shares of Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company's stock worth $30,000 after acquiring an additional 312 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health in the first quarter worth $30,000. Finally, Skandinaviska Enskilda Banken AB publ grew its stake in shares of Hims & Hers Health by 408.2% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company's stock worth $37,000 after acquiring an additional 600 shares during the last quarter. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.